Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 March 2022Website:
http://www.an2therapeutics.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:31:34 GMTDividend
Analysts recommendations
Institutional Ownership
ANTX Latest News
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
AN2 Therapeutics (NASDAQ: ANTX ) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study. AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease.
AN2 Therapeutics, Inc. (ANTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts. AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its p.
Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.
AN2 is a developer of rare, infectious disease therapeutics. AN2 leverages its boron chemistry expertise and has a history of a successful sale to Pfizer.
What type of business is AN2 Therapeutics?
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
What sector is AN2 Therapeutics in?
AN2 Therapeutics is in the Healthcare sector
What industry is AN2 Therapeutics in?
AN2 Therapeutics is in the Biotechnology industry
What country is AN2 Therapeutics from?
AN2 Therapeutics is headquartered in United States
When did AN2 Therapeutics go public?
AN2 Therapeutics initial public offering (IPO) was on 25 March 2022
What is AN2 Therapeutics website?
https://www.an2therapeutics.com
Is AN2 Therapeutics in the S&P 500?
No, AN2 Therapeutics is not included in the S&P 500 index
Is AN2 Therapeutics in the NASDAQ 100?
No, AN2 Therapeutics is not included in the NASDAQ 100 index
Is AN2 Therapeutics in the Dow Jones?
No, AN2 Therapeutics is not included in the Dow Jones index
When was AN2 Therapeutics the previous earnings report?
No data
When does AN2 Therapeutics earnings report?
The next expected earnings date for AN2 Therapeutics is 28 March 2025